secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2026-07-15T11:32:12+00:00
Accession:  0001628280-26-048248
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.02, 5.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Biosciences enters merger agreement with Celadon affiliate; stockholders to receive CVRs for SENTI-202 milestones
--------------------------------------------------------------------------------

- Celadon affiliate to acquire substantially all of Senti's business and pipeline via merger; Senti to remain public with streamlined structure.
- Stockholders will receive contingent value rights (CVRs) with potential payments up to $60M based on SENTI-202 BLA filing, FDA approval, and net sales milestones.
- Preliminary cash and cash equivalents of $6.5M as of June 30, 2026; combined with $6M additional funding from Celadon expected to fund operations through Q4 2026.
- Merger subject to stockholder approval and other conditions; expected to close in Q3 2026.
- Celadon, already largest stockholder with 54.6% ownership, could increase to up to 77.5% if additional notes are issued and exchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000162828026048248/0001628280-26-048248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000162828026048248/snti-20260714.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-048248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer